400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / PI3K/Akt/mTOR / PI3K / Umbralisib HCl/TGR-1202盐酸盐
CAS No.: 1532533-78-0
Synonyms: TGR-1202 hydrochloride;RP5264 hydrochloride;RP-5264 HCl
TGR-1202 HCl is an orally available, next generation PI3Kdelta inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT02793583 | Diffuse Large B-Cell Lymphoma ... more >> Follicular Lymphoma Marginal Zone Lymphoma Small Lymphocytic Lymphoma Mantle Cell Lymphoma Collapse << | Phase 2 Phase 3 | Recruiting | July 2019 | - |
NCT02006485 | Chronic Lymphocytic Leukemia ... more >> Non-Hodgkin's Lymphoma Collapse << | Phase 1 | Active, not recruiting | July 2019 | United States, Alabama ... more >> TG Therapeutics Investigational Trial Site Huntsville, Alabama, United States, 35805 United States, Arkansas TG Therapeutics Investigational Trial Site Jonesboro, Arkansas, United States, 72401 United States, California TG Therapeutics Investigational Trial Site Duarte, California, United States, 91010 United States, Georgia TG Therapeutics Investigational Trial Site Atlanta, Georgia, United States, 30322 United States, Nebraska TG Therapeutics Investigational Trial Site Omaha, Nebraska, United States, 68198 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT03269669 | Grade 1 Follicular Lymphoma ... more >> Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Recurrent Follicular Lymphoma Refractory Follicular Lymphoma Collapse << | Phase 2 | Recruiting | December 31, 2022 | - |
实验方案
技术信息
CAS号 | 1532533-78-0 | 储存条件 |
|
|
分子式 | C31H25ClF3N5O3 | 运输 | 蓝冰 | |
分子量 | 608.01 | 别名 | TGR-1202 hydrochloride;RP5264 hydrochloride;RP-5264 HCl;TGR-1202 HCl |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT02793583 | Diffuse Large B-Cell Lymphoma ... more >> Follicular Lymphoma Marginal Zone Lymphoma Small Lymphocytic Lymphoma Mantle Cell Lymphoma Collapse << | Phase 2 Phase 3 | Recruiting | July 2019 | - |
NCT02006485 | Chronic Lymphocytic Leukemia ... more >> Non-Hodgkin's Lymphoma Collapse << | Phase 1 | Active, not recruiting | July 2019 | United States, Alabama ... more >> TG Therapeutics Investigational Trial Site Huntsville, Alabama, United States, 35805 United States, Arkansas TG Therapeutics Investigational Trial Site Jonesboro, Arkansas, United States, 72401 United States, California TG Therapeutics Investigational Trial Site Duarte, California, United States, 91010 United States, Georgia TG Therapeutics Investigational Trial Site Atlanta, Georgia, United States, 30322 United States, Nebraska TG Therapeutics Investigational Trial Site Omaha, Nebraska, United States, 68198 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT03269669 | Grade 1 Follicular Lymphoma ... more >> Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Recurrent Follicular Lymphoma Refractory Follicular Lymphoma Collapse << | Phase 2 | Recruiting | December 31, 2022 | - |
NCT03269669 | Grade 1 Follicular Lymphoma ... more >> Grade 2 Follicular Lymphoma Grade 3a Follicular Lymphoma Recurrent Follicular Lymphoma Refractory Follicular Lymphoma Collapse << | Phase 2 | Recruiting | December 31, 2022 | - |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网